Study summary · research use only
Anti-aging activity of Syn-Ake peptide by in silico approaches and in vitro tests
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This in silico and in vitro study, species not specified, investigated the synthetic peptide Syn-Ake for potential anti-aging activity. Molecular docking indicated binding to matrix metalloproteinases (MMP-1, MMP-8, MMP-13) and to Sirtuin 1 (SIRT1), with the most stable binding to SIRT1 at -9.32 kcal/mol; a 50 ns molecular dynamics simulation showed the peptide remained stable at the MMP-13 and SIRT1 binding sites. Antioxidant activity was assessed using the DPPH assay, showing concentration-dependent radical scavenging. Cytotoxicity (MTT) and genotoxicity (Ames) tests were used to characterize a dose profile, and the authors describe the peptide as showing promise for anti-aging formulations based on these in silico and in vitro findings.
Abstract
The increase in the aging population worldwide has led scientists to turn to research to prevent the aging process. In this context, synthetic peptides emerge as candidate molecules for developing new anti-aging products. This study aims to investigate the possible interactions of Syn-Ake, a synthetic peptide, with matrix metalloproteinases (MMPs) and Sirtuin 1 (SIRT1), which are the targets of anti-aging activities with in silico approaches, and to determine the antioxidant activity, and safety profile of the peptide by in vitro methods such as cytotoxicity (MTT) and genotoxicity (Ames) tests. The molecular docking study showed that the docking score energy of MMP receptors was in the order of MMP-13 < MMP-8 < MMP-1. Syn-Ake peptide provided the lowest and the most stable binding to the SIRT1 receptor at -9.32 kcal/mol. Binding interaction and protein-ligand stability of Syn-Ake with MMPs and SIRT1 in a dynamic system were predicted by 50 ns molecular dynamic (MD) simulation studies. The MD results showed that the Syn-Ake peptide remained stable in the active site of MMP-13 and SIRT1 receptors during 50 ns simulations. In addition, the antioxidant activity of Syn-Ake was investigated using diphenyl-2-picril-hydrazine (DPPH) method since it is crucial to remove free radicals that are effective in skin aging. The results revealed the concentration-dependent increased DPPH radical scavenging activity of the peptide. Finally, the safety of the Syn-Ake was investigated, and the safe dose of the peptide was determined. In conclusion, in silico and in vitro analyses show that the Syn-Ake peptide may hold promise in anti-aging formulations with its high efficacy and safety profile.Communicated by Ramaswamy H. Sarma.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.